科伦药业股东刘革新质押916.7万股，占总股本0.57%

Core Viewpoint - Kelong Pharmaceutical (002422) has seen significant share pledges from major shareholders, indicating potential liquidity concerns amid declining financial performance [1][3]. Group 1: Share Pledge Details - Shareholder Liu Gexin pledged a total of 9.167 million shares to Huatai Securities (Shanghai) Asset Management Co., accounting for 0.57% of the total share capital [1]. - As of the announcement date, Liu Gexin has cumulatively pledged 103 million shares, representing 27.26% of his total holdings [1]. - Another major shareholder, Yaan State-owned Assets Management Co., has pledged 30.89 million shares, which is 31.85% of its total holdings [1]. Group 2: Shareholder Pledge Impact - The cumulative pledged shares of Kelong Pharmaceutical's top ten shareholders have reached a significant proportion of their holdings, indicating a trend of increasing leverage among major stakeholders [2]. - The data shows that the pledged shares are impacting the overall ownership structure and may affect investor sentiment [2]. Group 3: Financial Performance - Kelong Pharmaceutical reported a revenue of 4.39 billion yuan for Q1 2025, a year-on-year decline of 29.42% [3]. - The net profit attributable to shareholders was 584 million yuan, down 43.07% year-on-year, with a non-recurring net profit of 564 million yuan, also down 43.1% [3]. - The company's debt ratio stands at 27.48%, with investment income of 61.31 million yuan and financial expenses of 4.1268 million yuan, while the gross profit margin is at 48.67% [3].